<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0404233481
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KLACID 500MG COATED TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        90.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ABBVIE SRL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ABBVIE SRL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each KLACID contains 500 mg of the active ingredient clarithromycin. KLACID tablet<br />belongs to a group of medicines called macrolide antibiotics.<br />Antibiotics stop the growth of bacteria (bugs) which cause infections. KLACID tablets are<br />used to treat infections such as:<br />&bull; Upper respiratory tract infections for example, sinusitis, tonsillitis and pharyngitis.<br />&bull; Lower respiratory tract infections for example, acute and chronic bronchitis and pneumonia.<br />&bull; Skin and soft tissue infections of mild to moderate severity for example, impetigo,<br />erysipelas, folliculitis, cellulitis, furunculosis, and infected wounds.<br />&bull; Clarithromycin is appropriate for initial therapy in community acquired respiratory<br />infections and has been shown to be active in-vitro against common and atypical respiratory<br />pathogens.<br />&bull; Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is<br />indicated for the eradication of H.pylori in patients with duodenal ulcers.<br />KLACID Tablets are indicated in adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take KLACID tablets if you;<br />&bull; know that you are allergic to clarithromycin, other macrolide antibiotics such as<br />erythromycin or azithromycin, or any of the other ingredients in the tablets.</p><p>&bull; are taking medicines called ergot alkaloid tablets (e.g. ergotamine or dihydroergotamine)<br />or use ergotamine inhalers for migraine.<br />&bull; are taking medicines called terfenadine or astemizole (widely taken for hay fever or<br />allergies) or cisapride or domperidone (for stomach disorders) or pimozide (for mental<br />health problems) as combining these drugs can sometimes cause serious disturbances in<br />heart rhythm. Consult your doctor for advice on alternative medicines.<br />&bull; are taking other medicines which are known to cause serious disturbances in heart<br />rhythm.<br />&bull; are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known<br />as statins, used to lower levels of cholesterol (a type of fat) in the blood).<br />&bull; are taking oral midazolam (a sedative).<br />&bull; have abnormally low levels of potassium in your blood (hypokalaemia).<br />&bull; have severe liver disease with kidney disease.<br />&bull; or someone in your family has a history of heart rhythm disorders (ventricular cardiac<br />arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG,<br />electrical recording of the heart) called &quot;long QT syndrome&quot;.<br />&bull; are taking medicines called ticagrelor or ranolazine (for heart attack, chest pain or angina)<br />&bull; are taking colchicine (usually taken for gout)</p><p>Warnings and precautions<br />Talk to your doctor or pharmacist before taking KLACID tablets;<br />&bull; if you have heart problems (e.g. heart disease, heart failure, an unusually slow heart rate, or<br />abnormally low levels of magnesium in the blood (hypomagnesaemia))<br />&bull; if you have any liver or kidney problems<br />&bull; if you have, or are prone to, fungal infections (e.g. thrush)<br />&bull; if you are pregnant or breast feeding</p><p>KLACID tablets are not suitable for use in children under 12 years of age.<br />Other medicines and KLACID Tablets<br />You should not take Klacid tablets if you are taking any of the medicines listed in the<br />section above &ldquo;Do not take Klacid tablets if you;&rdquo;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines as your dose may need to be changed or you may need to have regular tests<br />performed:<br />&bull; digoxin, quinidine or disopyramide (for heart problems)<br />&bull; ibrutinib (for cancer treatment)<br />&bull; warfarin, or any other anticoagulant (for blood thinning)<br />&bull; carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)<br />&bull; atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as<br />statins, and used to lower levels of cholesterol (a type of fat) in the blood). Statins can<br />cause rhabdomyolosis (a condition which causes the breakdown of muscle tissue&nbsp;which can result in kidney damage) and signs of myopathy (muscle pain or muscle<br />weakness) should be monitored.</p><p>&bull; nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood<br />glucose levels)<br />&bull; gliclazide or glimepiride (sulphonylureas used in the treatment of type II diabetes)<br />&bull; theophylline (used in patients with breathing difficulties such as asthma)<br />&bull; triazolam, alprazolam or intravenous or oromucosal midazolam (sedatives)<br />&bull; cilostazol (for poor circulation)<br />&bull; methylprednisolone (a corticosteroid)<br />&bull; vinblastine (for treatment of cancer)<br />&bull; ciclosporin, sirolimus and tacrolimus (immune suppressants)<br />&bull; etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (antiviral<br />drugs used in the treatment of HIV)<br />&bull; rifabutin, rifampicin, rifapentine, fluconazole, itraconazole (used in the treatment of<br />certain bacterial infections)<br />&bull; tolterodine (for overactive bladder)<br />&bull; verapamil, amlodipine, diltiazem (for high blood pressure)<br />&bull; sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in<br />pulmonary arterial hypertension (high blood pressure in the blood vessels of the lung))<br />&bull; St John&rsquo;s Wort (a herbal product used to treat depression)<br />&bull; quetiapine or other antipsychotic medicines.<br />&bull; other macrolide medicines<br />&bull; lincomycin and clindamycin (lincosamides &ndash; a type of antibiotic)</p><p>Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby,<br />ask your doctor or pharmacist before taking this medicine as the safety of KLACID tablets<br />in pregnancy and breast-feeding is not known<br />Driving and Using Machines:<br />KLACID tablets may make you feel dizzy or drowsy. If they affect you in this way do not<br />drive, operate machinery or do anything that requires you to be alert.<br />Klacid tablets contains less than 1 mmol sodium (23 mg) per dosage unit, that is<br />to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not give these tablets to children under 12 years. Your doctor will prescribe another<br />suitable medicine for your child.<br />Always take KLACID tablets exactly as your doctor has told you. Check with your doctor or<br />pharmacist if you are not sure. The recommended dose is;<br />For chest infections, throat or sinus infections and skin and soft tissue infections: Usual<br />dose of KLACID tablets for adults and children over 12 years is 250 mg twice daily for 6 to&nbsp;14 days, e.g. one 250 mg tablet in the morning and one in the early evening. Your doctor may<br />increase the dose to 500 mg twice daily in severe infections.<br />KLACID tablets should be swallowed with at least half a glass of water.</p><p>For the treatment of Helicobacter pylori infection associated with duodenal ulcers:<br />There are a number of effective treatment combinations available to treat Helicobacter pylori<br />in which KLACID tablets are taken together with one or two other drugs.<br />These combinations include the following and are usually taken for 6 to 14 days:<br />a) One KLACID 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken<br />twice a day plus lansoprazole, 30 mg twice a day.<br />b) One KLACID 500 mg tablet taken twice a day together with metronidazole, 400 mg taken<br />twice a day plus lansoprazole, 30 mg twice a day.<br />c) One KLACID 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken<br />twice a day or metronidazole, 400 mg taken twice a day plus omeprazole, 40 mg a day.<br />d) One KLACID 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken<br />twice a day plus omeprazole, 20 mg taken once a day.</p><p>The treatment combination that you receive may differ slightly from the above. Your doctor<br />will decide which treatment combination is the most suitable for you. If you are unsure which<br />tablets you should be taking or how long you should be taking them for, please consult your<br />doctor for advice.</p><p>If you take more KLACID tablets than you should<br />If you accidentally take more KLACID tablets in one day than your doctor has told you to, or<br />if a child accidentally swallows some tablets, contact your doctor or nearest hospital<br />emergency department immediately. An overdose of KLACID tablets is likely to cause<br />vomiting and stomach pains.<br />If you forget to take KLACID tablets<br />If you forget to take an KLACID tablet, take one as soon as you remember. Do not take more<br />tablets in one day than your doctor has told you to.<br />If you stop taking KLACID tablets<br />Do not stop taking KLACID tablets, even if you feel better. It is important to take the tablets<br />for as long as the doctor has told you to, otherwise the problem might come back.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, KLACID tablets can cause side effects although not everybody gets them.<br />If you suffer from any of the following at any time during your treatment STOP TAKING<br />your tablets and contact your doctor immediately:</p><p>&bull; severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may<br />occur over two months after treatment with clarithromycin, in which case you should<br />still contact your doctor.<br />&bull; a rash, difficulty breathing, fainting or swelling of the face, tongue, lips, eyes and<br />throat. This is a sign that you may have developed an allergic reaction.<br />&bull; yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen<br />or loss of appetite. These may be signs that your liver may have inflammation and not<br />be working properly.<br />&bull; severe skin reactions such as painful blistering of the skin, mouth, lips, eyes and<br />genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic<br />epidermal necrolysis).<br />&bull; a red, scaly rash with bumps under the skin and blisters (symptoms of<br />exanthematous pustulosis). The frequency of this side effect is not known<br />(cannot be estimated from the available data).<br />&bull; rare allergic skin reactions which cause severe illness with ulceration of the<br />mouth, lips and skin which causes severe illness with rash, fever and<br />inflammation of internal organs (DRESS).<br />&bull; muscle pain or weakness known as rhabdomyolysis (a condition which causes the<br />breakdown of muscle tissue which can result in kidney damage).</p><p>Other side effects:<br />Common side effects (may affect up to 1 in 10 people) include;<br />&bull; difficulty sleeping<br />&bull; changes in sense of taste<br />&bull; headache<br />&bull; widening of blood vessels<br />&bull; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea<br />&bull; increased sweating<br />Uncommon side effects (may include up to 1 in 1 00 people) include:<br />&bull; high temperature<br />&bull; swelling, redness or itchiness of the skin<br />&bull; oral or vaginal &#39;thrush&#39; (a fungal infection)<br />&bull; inflammation of the stomach and intestines<br />&bull; decrease of the levels of blood platelets (blood platelets help stop bleeding)<br />&bull; decrease in white blood cells (leukopenia)<br />&bull; decrease in neutrophils (neutropenia)<br />&bull; stiffness<br />&bull; chills<br />&bull; increase of eosinophils (white blood cells involved in immunity)<br />&bull; exaggerated immune response to a foreign agent<br />&bull; lack or loss of appetite<br />&bull; anxiety, nervousness<br />&bull; drowsiness, tiredness, dizziness or shaking<br />&bull; involuntary muscle movements</p><p>&bull; vertigo<br />&bull; ringing in the ears or hearing loss<br />&bull; chest pain or changes in heart rhythm such as palpitations or an irregular heartbeat<br />&bull; asthma: lung disease associated with tightening of air passages, making breathing difficult<br />&bull; nose bleed<br />&bull; blood clot that causes sudden blockage in a lung artery (pulmonary embolism)<br />&bull; inflammation of the lining of the gullet (oesophagus) and lining of the stomachanal pain<br />&bull; bloating, constipation, wind, burping<br />&bull; dry mouth<br />&bull; situation where the bile (fluid made by the liver and stored in the gallbladder) cannot flow<br />from the gallbladder to the duodenum (cholestasis)<br />&bull; inflammation of the skin characterized by the presence of the bullae which are filled with<br />fluid, itchy and painful rash<br />&bull; muscle spasms, muscle pain or loss of muscle tissue. If your child suffers from myasthenia<br />gravis (a condition in which the muscles become weak and tire easily), clarithromycin may<br />worsen these symptoms.<br />&bull; raised abnormal kidney and liver function&nbsp;blood test and raised blood tests<br />&bull; feeling weak, tired and having no energy</p><p>Not known side effects (frequency cannot be estimated from the available data):<br />&bull; inflammation of the colon<br />&bull; bacterial infection of the outer layers of the skin<br />&bull; reduction in the level of certain blood cells (which can make infections more likely or<br />increase the risk of bruising or bleeding)<br />&bull; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or<br />panicking, depression, abnormal dreams or nightmares and mania (feeling of elation or<br />over-excitement)<br />&bull; convulsion (fits)<br />&bull; paraesthesia, more commonly known as &#39;pins and needles&#39;<br />&bull; loss of taste or smell or inability to smell properly<br />&bull; type of heart rhythm disorder (Torsade de pointes, ventricular tachycardia)<br />&bull; loss of blood (haemorrhage)<br />&bull; inflammation of the pancreas<br />&bull; discolouration of the tongue or teeth<br />&bull; acne<br />&bull; change in the levels of products produced by the kidney, inflammation of the kidney or an<br />inability of the kidney to function properly (you may notice tiredness, swelling or<br />puffiness in the face, abdomen, thighs or ankles or problems with urination)</p><p>Reporting side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side<br />effects not listed in this leaflet. By reporting side effects you can help provide more<br />information on the safety of this medicine.</p><p>To report any side effect(s):<br />-National Pharmacovigilance Center (NPC)<br />o Fax: +966-1-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />oToll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children<br />Shelf life: 36 months<br />Do not use these tablets after their use-by (exp) date that is printed on the box and indented on<br />the blister strip.<br />Store below 25&deg;C.<br />Keep these tablets in a dry, safe place, protected from light.<br />Do not throw away any medicines via wastewater or household water. Ask your pharmacist<br />how to throw away medicines you no longer use. These measures will help protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What KLACID tablets contain<br />Each KLACID tablet contains 500 mg of the active ingredient clarithromycin.<br />The other ingredients are; quinolone yellow (E104 aluminium lake), sodium croscarmellose,<br />microcrystalline cellulose, silicon dioxide, povidone, stearic acid, magnesium stearate, talc,<br />hypromellose, propylene glycol, sorbitan monooleate, titanium dioxide, vanillin,<br />Hydroxypropylcellulose and sorbic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What KLACID tablets look like and contents of the pack
KLACID 500 mg tablets are yellow, oval and plain.
KLACID 500 mg tablets are available as calendar packs containing 14 and 20 tablets
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />Abbott Laboratories Ltd.<br />Abbott House, Vanwall Business park<br />Vanwall Road, Maidenhead Berkshire<br />SL6 4XE, UK</p><p>Manufacturer<br />Aesica Queenborough Limited,<br />North Road Queenborough, Kent ME 11 5EL, UK</p><p>Packaged by<br />Riyadh Pharma<br />Medical and cosmotic products Co .ltd<br />Riyadh &ndash; Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">یحتوي كل قرص كلاسید على 500 ملغم من المادة الفعالة كلاریثرومایسین التي تنتمي إلى مجموعة من المضادات الحیویة تسمى ماكرولید.</p><p dir="RTL">المضادات الحیویة تعمل على وقف نمو البكتیریا( المیكروبات) التي تسبب العدوى. تستخدم أقراص كلاسید لعلاج الالتھابات مثل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجھاز التنفسي العلوي مثل التھاب الجیوب الأنفیة، التھاب اللوزتین، والتھاب الحلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجھاز التنفسي السفلي مثل التھاب الشعب الحاد أو المزمن والتھاب الرئة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الخفیفة أو متوسطة الخطورة في الجلد والأنسجة الرخوة، مثل الحصف، الحمرة ،التھاب الأجربة، والتھاب النسیج الخلوي الرخو تحت الجلد، الدمامل ،والجروح المتقیحة&nbsp; .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یعُتبر كلاریثرومیسین مناسباً للعلاج الأولي في حالات التھابات الجھاز التنفسي المكتسبة من المجتمع وقد ثبت أنھ فعال في المختبر ضد مسببات الأمراض التنفسیة الشائعة كما ھو موضح في قسم المیكروبیولوجیا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یتم أیضًا وصف كلاریثرومیسین عند وجود حالة كبت الأحماض الناجمة عن أومیبرازول أو لانسوبرازول من أجل استئصال الملویة البوابیة لدى المرضى الذین یعانون من القرحة الإثنى عشریة&nbsp; .</p><p dir="RTL">أقراص كلاسید مخصصة للبالغین والأطفال من سن 12 عام فأكبر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل كلاسید إذا كنت: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرف أن لدیك حساسیة من كلاریثرومایسین، والمضادات الحیویة الأخرى التي تنتمي إلى مجموعة ماكرولید مثل اریثرومیسین أو أزیثرومیسین، أو من أي من المكونات الأخرى في الأقراص.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدویة تسمى أقراص قلویدات الأرجوت (مثل الإرجوتامین أو دایھیدروإرجوتامین) أو تستعمل بخاخات الإرجوتامین للاستنشاق لعلاج الصداع النصفي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدویة تسمى ترفینادین أو أستیمیزول (تؤخذ على نطاق واسع لحمى الكلأ أو الحساسیة) أو سیسابرید أو دومبیریدون (لاضطرابات المعدة) أو بیموزید (لمشاكل الصحة النفسیة) حیث إن تناول ھذه الأدویة معاً یمكن أن یسبب أحیاناً اضطرابات خطیرة في انتظام ضربات القلب. استشر طبیبك للحصول على المشورة بشأن تناول الأدویة البدیلة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدویة أخرى من المعروف أنھا تسبب اضطرابات خطیرة في انتظام ضربات القلب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول لوفاستاتین أو سیمفاستاتین (مثبطات مختزلة HMG-CoA المعروفة باسم الستاتینات، والتي تسُتخدم لخفض مستویات الكولسترول (نوع من الدھون) في الدم.) &bull; &nbsp;&nbsp; تتناول میدازولام عن طریق الفم (مھدئ.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من انخفاض مستویات البوتاسیوم في الدم بشكل غیر طبیعي (نقص بوتاسیوم الدم.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصاباً بأمراض كبدیة <strong>شدیدة</strong> مع أمراض الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شخصاً ما في عائلتك لدیھ تاریخ من اضطرابات ضربات القلب (عدم انتظام ضربات القلب البطیني، بما في ذلك حالة تورساد دي بوانت) أو شذوذ مخطط كھربائیة القلب (خلل في رسم القلب والتسجیل الكھربائي للقلب) یسمى &quot;متلازمة كیو تي الطویلة.&quot; &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدویة تسمى تیكاجریلور أو رانولازین (للنوبة القلبیة أو لألم الصدر أو الذبحة الصدریة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول الكولشیسین (عادة ما یؤخذ للنقرس)</p><p dir="RTL"><strong>التحذیرات والاحتیاطات: </strong></p><p dir="RTL">تحدث مع طبیبك أو الصیدلي قبل تناول أقراص كلاسید في الحالات التالیة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب (مثل أمراض القلب أو قصور القلب أو بطء في معدل ضربات القلب بشكل غیر عادي أو الانخفاض غیر الطبیعي لمستویات المغنیسیوم في الدم (نقص ماغنسیوم الدم))&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لدیك أي مشاكل في الكبد أو الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لدیك، أو عرضة للعدوى الفطریة (على سبیل المثال القلاع)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو في مرحلة الرضاعة الطبیعیة</p><p>&nbsp;</p><p><strong>أقراص كلاسید غیر مناسبة للأطفال أصغر من سن 12 عام. </strong></p><p>&nbsp;</p><p dir="RTL"><strong>الإستخدام مع الأدویة الأخرى: </strong></p><p dir="RTL">ینبغي <strong>ألا</strong> تتناول أقراص كلاسید إن كنت تتناول أیاًّ من الأدویة المبینة في القسم المذكور أعلاه &quot;لا تتناول أقراص كلاسید إن كنت؛&quot;</p><p dir="RTL">أخبر طبیبك أو الصیدلي أو الممرضة إذا كنت تتناول، أو تناولت مؤخراً أو قد تتناول مستقبلاً أي أدویة أخرى، حیث قد تكون ھناك حاجة إلى تغییر جرعة كلاسید التي تتناولھا أو إجراء بعض الفحوصات بانتظام:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دیجوكسین أو كویندین أو دیزوبرامید (لعلاج مشكلات القلب.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابروتینیب (لعلاج السرطان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارین أو أي من مضادات التجلط الأخرى (لإسالة الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازیبین، ڤالبروات، فینوباربیتال أو فیناتون (أدویة الصرع.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتورفاستاتین، روسوفاستاتین (مثبطات مختزلة HMG-CoA المعروفة على نحو شائع باسم الستاتینات، والتي تسُتخدم لخفض مستویات الكولسترول (نوع من الدھون) في الدم). الستاتینات یمكنھا أن تسبب انحلال العضلات المخططـة الھیكلیـة (الحالة التي یحدث فیھا انھیار الأنسجة العضلیة والتي یمكن أن تؤدي إلى تلف الكلى) ومن ثم ینبغي مراقبة أعراض الاعتلال العضلي (آلام العضلات أو ضعف العضلات.)</p><p>ناتیجلینیدین، بیوجلیتازون، ریباجلینید، روزیجلیتازون أو الأنسولین (التي تستخدم لخفض مستویات الجلوكوز في الدم.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلیكلازید أو جلیمیبیرید (أدویة السلفونیل یوریا المستخدمة في علاج النوع الثاني من مرض السكري)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثیوفیللین (یسُتخدم في علاج المرضى المصابین بصعوبات تنفسیة مثل الربو.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترایازولام، البرازولام، میدازولام للغشاء المخاطي الفموي أو للاستخدام عن طریق الورید (مھدئ.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیلوستازول (لعلاج قصور الدورة الدمویة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; میثیل بردنیزولون (كورتیكوستیروید.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ڤینبلاستین (لعلاج السرطان.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیكلوسبورین، سیرولیمیس، تاكرولیمیس (مثبطات المناعة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إترافیرین، إیفافیرنز، نیفیرابین، ریتونافیر، زیدوفودین، أتازانافیر، ساكینافیر (الأدویة المضادة للفیروسات المستخدمة في علاج فیروس نقص المناعة البشریة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ریفابیوتین، ریفامبیسین، ریفابنتین، فلوكانازول، أیتراكونازول (تسُتخدم في علاج بعض الالتھابات البكتیریة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولتیرودین (لعلاج فرط نشاط المثانة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فیرابامیل، أملودیبین، دیلتیازیم (لارتفاع ضغط الدم.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیلدینافیل، فاردینافیل، تادالافیل (لعلاج العجز الجنسي عند الذكور البالغین أو للاستخدام في ارتفاع ضغط الدم الشریاني الرئوي (ارتفاع ضغط الدم في الأوعیة الدمویة في الرئة.))</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة سانت جون (منتج عشبي یسُتخدم لعلاج الاكتئاب.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كیتیابین أو الأدویة الأخرى المضادة للذھان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدویة الماكرولیدیة الأخرى</p><p>لینكومیسین وكلیندامایسین (لینكوسامیدس - نوع من المضادات الحیویة</p><p dir="RTL"><strong>الحمل والرضاعة: </strong></p><p dir="RTL">إذا كنت حاملاً، أو ترضعین طفلك رضاعة طبیعیة أو تعتقدین أنك قد تكونین حاملاً، أو تخططین للحمل، فیجب استشارة &nbsp;طبیبكِ أو الصیدلي قبل تناول ھذا الدواء حیث إن سلامة استخدام أقراص كلاسید في الحمل والرضاعة غیر معروفة.</p><p dir="RTL"><strong>القیادة وإستخدام الآلات: </strong></p><p dir="RTL">كل أقراص كلاسید قد تجعلك تشعر بالدوار أو النعاس. إذا كان ھذا الدواء یؤثر علیك بھذه الطریقة، فیجب عدم القیادة أو &nbsp;تشغیل الآلات أو القیام بعمل یتطلب منك ان تكون في حالة یقظة.</p><p dir="RTL">تحتوي أقراص كلاسید على أقل من 1 ملیمول من الصودیوم( 23 مجم) لكل جرعة، أي &quot;خالٍ من الصودیوم &quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تعطِ ھذه الأقراص للأطفال دون سن 12 عاماً. وسوف یصف الطبیب الدواء المناسب لطفلك</p><p dir="RTL">یجب تناول جرعة كلاسید كما یصفھا الطبیب. یجب علیك أن تستشیر طبیبك أو الصیدلى إذا كنت غیر متأكد من &nbsp;الجرعة، الجرعة المعتادة ھي:</p><p dir="RTL"><strong>لالتھابات الصدر والتھابات الحلق أو الجیوب الأنفیة والتھابات الجلد والأنسجة اللینة: </strong>الجرعة المعتادة من أقراص كلاسید للبالغین والأطفال فوق 12 سنة ھي 250 ملغم مرتین یومیا ً صباحاً ومساءاً لمدة 6 إلى 14 یوما. وقد یحتاج طبیبك لزیادة الجرعة إلى 500 ملغم مرتین یومیاً في العدوى الشدیدة. یجب ابتلاع الأقراص مع ما لا یقل عن &nbsp;نصف كوب ماء.</p><p dir="RTL"><strong>&nbsp;لعلاج عدوى الملویة البوابیة والمرتبطة بقرحة الاثني عشر:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ھناك عدد من مجموعات العلاج الفعالة المتاحة لعلاج الملویة البوابیة<strong> </strong>حیث یتم تناول<strong> أقراص كلاسید مع واحد أو&nbsp; اثنین من الأدویة الأخرى:</strong></p><p dir="RTL">&nbsp;وتشمل ھذه المجموعات ما یلي، وعادة ما تؤخذ لمدة 6 إلى 14 یوما:</p><p dir="RTL">أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرص واحد كلاسید 500 ملغم + قرص 1000 ملغم أموكساسیلین+ &nbsp;قرص واحد 30 ملغم لانزوبرازول مرتین یومیا ً.</p><p dir="RTL">ب&zwnj;-&nbsp;&nbsp; قرص واحد كلاسید 500 ملغم + قرص واحد 400 ملغم میترونیدازول+ &nbsp;قرص واحد 30 ملغم لانزوبرازول مرتین&nbsp; یومیاً.</p><p dir="RTL">ت&zwnj;-&nbsp;&nbsp; قرص واحد كلاسید 500 ملغم مرتین یومیاً + قرص واحد 1000 ملغم أموكساسیلین مرتین یومیاً + قرص واحد 400 ملغم میترونیدازول مرتین یومیاً + قرص واحد 40 ملغم أومیبرازول مرة واحدة یومیا ً.</p><p dir="RTL">ث&zwnj;-&nbsp;&nbsp; قرص واحد كلاسید 500 ملغم مرتین یومیاً + قرص واحد 1000 ملغم أموكساسیلین مرتین یومیاً + قرص واحد 20 ملغم أومیبرازول مرة واحدة یومیا ً.</p><p dir="RTL">وسوف یقرر الطبیب أي تركیبة علاج ھي الأنسب بالنسبة لك. یرجى استشارة الطبیب للحصول على المشورة إذا &nbsp;كنت غیر متأكد من نوع التركیبات ومدة العلاج أو إذا كان ھناك تركیبة العلاج تختلف قلیلاً عن ما سبق</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من أقراص كلاسید:</strong></p><p dir="RTL">إذا تناولت أكثر من الجرعة المقررة من أقراص كلاسید بطریق الخطأ في یوم واحد، أو إذا ابتلع الطفل بعض الأقراص</p><p dir="RTL">بطریق الخطأ، فاتصل بالطبیب أو بأقرب مستشفى أو قسم طوارئ عَلى الفور حیث قد تتسبب الجرعة الزائدة من أقراص &nbsp;كلاسید في التقیؤ وآلام في المعدة.</p><p dir="RTL"><strong>إذا نسیت أن تتناول أقراص كلاسید: </strong></p><p dir="RTL">إذا نسیت أن تتناول جرعة من أقراص كلاسید، فیمكنك تناولھا في أقرب وقت تتذكرھا. لا تتناول أكثر من الجرعة التي &nbsp;وصفھا لك الطبیب في یوم واحد.</p><p dir="RTL"><strong>التوقف عن تناول كلاسید:</strong></p><p dir="RTL">لا تتوقف عن تناول أقراص كلاسید، حتى لو كنت تشعر بتحسن ومن المھم أن تتناول الأقراص على مدار المدة التي &nbsp;حددھا لك الطبیب، وإلا فإن المرض قد یعود مرة أخرى.</p><p dir="RTL">&nbsp;إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء، فاسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;مثل جمیع الأدویة، یمكن أن تسبب أقراص كلاسید بعض الآثار الجانبیة على الرغم من عدم حدوث ذلك لكل الأشخاص.</p><p dir="RTL">إذا كنت تعاني من أي من الأعراض التالیة في أي وقت أثناء العلاج، فیجب وقف تناول الأقراص والاتصال بالطبیب &nbsp;على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسھال الشدید أو الإسھال لفترات طویلة، والذي قد یكون مختلطاً بھ دم أو مخاط. قد یحدث الإسھال على مدى أكثر من شھرین بعد العلاج بالكلاریثرومایسین وإذا حدث ذلك، ففي ھذه الحالة یجب الاتصال بالطبیب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، أو صعوبة التنفس، أو الإغماء، أو تورم الوجھ أو اللسان أو الشفتین أو العینین أو الحلق. وھذه علامة على احتمال إصابتك برد فعل تحسسي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (الیرقان)، أو تھیج الجلد، أو البراز فاتح اللون، أو البول غامق اللون، أو إیلام البطن عند لمسھا، أو فقدان الشھیة .وتلك علامات على أن كبدك قد یكون مصاباً بالالتھاب وأنھ قد لا یؤدي وظیفتھ بشكل سلیم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدیة شدیدة مثل تقرحات مؤلمة في الجلد والفم والعینین والشفتین والأعضاء التناسلیة، (أعراض لتفاعل حساسیة نادر یسمى متلازمة ستیفنز جونسون/ تقشر الأنسجة المتموتة البشرویة التسممي.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر ومتقشر، مع تحادیب تحت الجلد وبثور (أعراض البثار الطفحي). معدّل تكرار ھذا الأثر الجانبي مجھول (أي لا یمكن تقدیر ه من خلال البیانات المتاحة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسیة حادة بالجلد تسبب مرضاً شدیداً مصحوباً بتقرّح الفم والشفتین والجلد، مما یسبب مرضاً شدیداً یصاحبھ طفح جلدي وحمى والتھاب الأعضاء الداخلیة (متلازمة DRESS).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف في العضلات یعُرف باسم انحلال الربیدات (وھي حالة تتسبب في انھیار الأنسجة العضلیة والتي یمكن أن تؤدي إلى تلف الكلى.)</p><p dir="RTL">&nbsp;<strong>آثار جانبیة أخرى </strong></p><p dir="RTL">الآثار الجانبیة الشائعة (قد تؤثر على ما یصل إلى 1 من أصل 10 أشخاص) وتشمل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغیرات في حاسة التذوق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتساع الأوعیة الدمویة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في المعدة مثل الشعور بالإعیاء، والتقیؤ، وآلام في المعدة، وعسر الھضم، والإسھال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة التعرق</p><p dir="RTL">الآثار الجانبیة غیر الشائعة (قد تؤثر على ما یصل إلى 1 من أصل 100 شخص) وتشمل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، احمرار أو حكة في الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطریة بالفم أو المھبل (القلاع)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب المعدة والأمعاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات الصفائح الدمویة (الصفائح الدمویة تساعد على وقف النزیف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلایا الدم البیضاء (نقص الكریات البیض)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شاذ في تعداد الكریات البیض المعتدلة (نقص العدلات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعریرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة الحمضات (ارتفاع مستوى الكریات البیضاء الحمِضة المساعدة في المناعة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة الاستجابة المناعیة للأجسام الغریبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشھیة أو فقدانھا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق والعصبیة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، تعب، دوخة أو رعشة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادیة بالعضلات &nbsp;</p><p>&bull;&nbsp; &nbsp; &nbsp; &nbsp;الدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنین في الأذنین أو فقدان السمع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو تغیرات في إیقاع نبض القلب مثل الخفقان أو عدم انتظام ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو: أمراض الرئة المرتبطة بضیق الممرات الھوائیة، مما یجعل التنفس&nbsp;صعباً</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف الأنف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم الذي یسبب &nbsp;&nbsp;&nbsp; &nbsp;انسداداً مفاجئاً في شریان الرئة (الانصمام الرئوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب بطانة المريء وبطانة المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالشرج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاخ والإمساك وخروج الغازات من البطن والتجشؤ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ركود الصفراء (السوائل التي یفرزھا الكبد وتخزن في المرارة) وفي ھذه الحالة لا یمكن أن تتدفق الصفراء من المرارة إلى الاثني عشر (الركود الصفراوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الجلد الذي یتمیز بوجود فقاعات ملیئة بالسوائل، وبالطفح الجلدي المؤلم والمثیر للحكة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات، آلام في العضلات أو فقدان الأنسجة العضلیة. إذا كان طفلك یعاني من الوھن العضلي الوبیل</p><p dir="RTL">(وھي حالة تصبح فیھا العضلات ضعیفة ویصیبھا التعب بسھولة)، فقد یؤدي كلاریثرومایسین إلى تفاقم ھذه الأعراض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج مرتفعة وغیر طبیعیة لاختبارات الدم لوظائف الكلى والكبد وغیرھا من اختبارات الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتعب وفقدان الطاقة</p><p dir="RTL">الآثار الجانبیة غیر المعروفة (لا یمكن تقدیر معدل تكرارھا من البیانات المتاحة:)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب القولون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بكتیریة في الطبقات الخارجیة من الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بعض خلایا الدم (التي یمكن أن تزید من احتمالیة الإصابة بالعدوى أو تزید من خطر الكدمات أو النزیف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك، وفقدان إدراك الاتجاھات، والھلوسة (رؤیة أشیاء غیر حقیقیة)، وتغییر الشعور بالواقع أو الفزع ،والاكتئاب، والأحلام غیر الطبیعیة أو الكوابیس والھوس (الشعور بالزھو والانتشاء أو فرط الاستثارة) &bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج (نوبات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنمیل، وغالباً ما یتم الشعور بھ على ھیئة إحساس بوخذ الدبابیس والإبر &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة التذوق أو الشم أو عدم القدرة على الشم بشكل صحیح</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من اضطراب ضربات القلب (تورساد دي بوانت، تسرع القلب البطیني)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الدم (النزف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب البنكریاس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغیر لون اللسان أو الأسنان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغیر في مستویات إفرازات الكلى، التھاب الكلى أو عدم قدرة الكلى على العمل بشكل صحیح (قد تلاحظ التعب ،التورم أو الانتفاخ في الوجھ والبطن والفخذین أو الكاحلین أو مشكلات في التبول)</p><p>&nbsp;</p><p dir="RTL">إذا أصُبت بأي من ھذه الأعراض الجانبیة، فأبلغ الطبیب المعالج أو الصیدلي.. وھذا یشمل أي آثار جانبیة محتملة غیر مدرجة في ھذه النشرة. بالإبلاغ عن الآثار الجانبیة، یمكنك المساعدة في توفیر مزید من المعلومات حول أمان ھذا الدواء.</p><p dir="RTL">للإبلاغ عن الأعراض الجانبیة<br />(NPC) - المركز الوطني للتیقظ والسلامة الدوائیة<br />+966-1-205- فاكس 7662 o<br />2317-2356-2353-2354- 966 +، تحویلة: - 2334 -11- الاتصال على المركز الوطني للتیقظ والسلامة الدوائیة على الرقم 2038222 o<br />2340<br />الھاتف المجاني: 8002490000 o<br />npc.drug@sfda.gov.sa : البرید الإلكتروني o<br />www.sfda.gov.sa/npc : الموقع الإلكتروني o</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; یحفظ بعیدا عن متناول أیدي الأطفال ومرآھم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; فترة الصلاحیة: 36 شھرا ً</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ھذه الأقراص بعد تاریخ انتھاء الصلاحیة المطبوع على الشریط والعلبة الخارجیة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; یحفظ في درجة حرارة أقل من 25 درجة مئویة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تحفظ ھذه الأقراص في مكان جاف وآمن ومحمیة من الضوء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; لا ینبغي أن یتم التخلص من الأدویة في میاه الصرف الصحي أو عن طریق النفایات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد مطلوبة. ھذه التدابیر تساعد في الحفاظ على البیئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یحتوي كل قرص كلاسید على المادة الفعالة كلاریثرومیسین بتركیز 500 ملغم.</p><p dir="RTL">الصواغات الأخرى ھي: الكینولون الأصفر( E104)، كروسكارملوس الصودیوم، السلیلوز دقیق التبلور ، ثاني أكسید السیلیكون ، البوفیدون ، حامض ستیاریك ، ستیرات المغنیسیوم ، التلك ، ھیدروكسي بروبیلین جلیكول ، سوربیتان أحادي الأولییت ، ثاني أكسید التیتانیوم ، فانیلین، ھیدروكسي بروبیل السیللوز ، وحمض السوربیك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما ھو شكل كلاسید ومحتویات العلبة؟</strong></p><p dir="RTL">&nbsp;أقراص كلاسید 500 ملغم عبارة عن أقراص صفراء، بیضاویة ملساء.</p><p dir="RTL">تتوافر أقراص كلاسید 500 ملغم في شرائط مطبوع علیھا تقویم تحتوي على 14 و20 قرص .</p><p>قد لا تتوفر كافة العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسویق: </strong></p><p dir="RTL">أبوب لابوراتوریز لیمیتد، أبوت ھاوس، فانوال بزنس بارك،</p><p dir="RTL">فانوال رود، میدینھید بیركشر، إس إل 6 4 إكس إي، المملكة المتحدة &nbsp;</p><p dir="RTL"><strong>المصنع: </strong></p><p dir="RTL">إیسیكا كوینبوروغ لیمیتد،</p><p dir="RTL">نورث رود كوینبوروغ، كینت إم إي 11 5 إي إل - المملكة المتحدة <strong>تم التغلیف في: </strong></p><p dir="RTL">مصنع الریاض فارما للصناعات الدوائیة ومستحضرات التجمیل الریاض، المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Klacid® 500 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One tablet contains 500 mg clarithromycin.
Excipient with known effect: sodium 6.1 mg per tablet
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A yellow, ovaloid film-coated tablet containing 500 mg of clarithromycin, plain on
both sides.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />Consideration should be given to official guidance on the appropriate use of<br />antibacterial agents.<br />Klacid 500mg Tablets are indicated in adults and children 12 years and older.<br />Clarithromycin is indicated for treatment of infections caused by susceptible<br />organisms. Indications include:<br />Lower respiratory tract infections for example, acute and chronic bronchitis, and<br />pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).<br />Upper respiratory tract infections for example, sinusitis and pharyngitis.<br />Clarithromycin is appropriate for initial therapy in community acquired<br />respiratory infections and has been shown to be active in vitro against common<br />and atypical respiratory pathogens as listed in the microbiology section.</p><p>Clarithromycin is also indicated in skin and soft tissue infections of mild to<br />moderate severity (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and<br />5.1 regarding Sensitivity Testing).<br />Clarithromycin in the presence of acid suppression effected by omeprazole or<br />lansoprazole is also indicated for the eradication of H. pylori in patients with<br />duodenal ulcers. See Dosage and Administration section.</p><p>Clarithromycin is usually active against the following organisms in vitro:<br />Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible);<br />Streptococcus pyogenes (Group A beta-haemolytic streptococci); alpha- haemolytic<br />streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae;<br />Streptococcus agalactiae; Listeria monocytogenes.<br />Gram-negative Bacteria: Haemophilus influenzae; Haemophilus<br />parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae;<br />Legionella pneumophila; Bordetella pertussis; Helicobacter pylori;<br />Campylobacter jejuni.<br />Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.<br />Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium<br />leprae.<br />Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens;<br />Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.</p><p>Clarithromycin has bactericidal activity against several bacterial strains. The<br />organisms include Haemophilus influenzae; Streptococcus pneumoniae;<br />Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella)<br />catarrhalis; Neisseria gonorrhoeae; H. pylori and Campylobacter spp.<br />The activity of clarithromycin against H. pylori is greater at neutral pH than at acid<br />pH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with respiratory tract/skin and soft tissue infections.<br />Adults: The usual dose is 250 mg twice daily although this may be increased to<br />500mg twice daily in severe infections. The usual duration of treatment is 6 to 14<br />days.<br />Children older than 12 years: As for adults. Children<br />younger than 12 years:<br />Use of Klacid 500mg Tablets are not recommended for children younger than<br />12 years. Clinical trials have been conducted using clarithromycin<br />paediatric suspension in children 6 months to 12 years of age. Therefore, children<br />under 12 years of age should use clarithromycin paediatric suspension (granules for<br />oral suspension).<br />Clarithromycin may be given without regard to meals as food does not affect the<br />extent of bioavailability.</p><p>Eradication of H. pylori in patients with duodenal ulcers (Adults) The<br />usual duration of treatment is 6 to 14 days.<br />Triple Therapy<br />Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily should be<br />given with amoxycillin 1000mg twice daily.<br />Triple Therapy<br />Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily should be<br />given with metronidazole 400mg twice daily.<br />Triple Therapy<br />Clarithromycin (500mg) twice daily and omeprazole 40mg daily should be<br />given with amoxycillin 1000mg twice daily or metronidazole 400mg twice<br />daily.<br />Triple Therapy<br />Clarithromycin (500mg) twice daily and omeprazole 20mg daily should be given<br />with amoxycillin 1000mg twice daily.</p><p>Elderly: As for adults.<br />Renal impairment:<br />In patients with renal impairment with creatinine clearance less than<br />30 mL/min, the dosage of clarithromycin should be reduced by one-half, i.e. 250<br />mg once daily, or 250 mg twice daily in more severe infections. Treatment should<br />not be continued beyond 14 days in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to macrolide antibiotic drugs or to any of the excipients listed in
section 6.1.
Concomitant administration of clarithromycin and ergot alkaloids (e.g.
ergotamine or dihydroergotamine) is contraindicated, as this may result in
ergot toxicity (see section 4.5).
Concomitant administration of clarithromycin and oral midazolam is
contraindicated (see section 4.5).
Concomitant administration of clarithromycin and any of the following drugs is
contraindicated: astemizole, cisapride, domperidone, pimozide and terfenadine as
this may result in QT prolongation and cardiac arrhythmias, including ventricular
tachycardia, ventricular fibrillation, and torsades de pointes (see section 4.4 and
4.5).
Clarithromycin should not be given to patients with history of QT prolongation
(congenital or documented acquired QT prolongation) or ventricular cardiac
arrhythmia, including torsades de pointes (see sections 4.4 and 4.5).
Concomitant administration with ticagrelor or ranolazine is contraindicated.
Clarithromycin should not be used concomitantly with HMG-CoA reductase
inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or
simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see
section 4.5).
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in
patients taking colchicine (see sections 4.4 and 4.5).
Clarithromycin should not be given to patients with hypokalaemia (risk of
prolongation of QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic
failure in combination with renal impairment.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use of any antimicrobial therapy, such as clarithromycin, to treat H. pylori<br />infection may select for drug-resistant organisms.<br />The physician should not prescribe clarithromycin to pregnant women without<br />carefully weighing the benefits against risk, particularly during the first three<br />months of pregnancy (see section 4.6).<br />Clarithromycin is principally metabolised by the liver. Therefore, caution should<br />be exercised in administering this antibiotic to patients with impaired hepatic<br />function.<br />Caution should also be exercised when administering clarithromycin to patients<br />with moderate to severe renal impairment (see section 4.2).<br />Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or<br />cholestatic hepatitis, with or without jaundice, has been reported with<br />clarithromycin. This hepatic dysfunction may be severe and is usually reversible.<br />Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients<br />may have had pre-existing hepatic disease or may have been taking other<br />hepatotoxic medicinal products. Patients should be advised to stop treatment and<br />contact their doctor if signs and symptoms of hepatic</p><p>disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender<br />abdomen.<br />Pseudomembranous colitis has been reported with nearly all antibacterial agents,<br />including macrolides, and may range in severity from mild to life- threatening.<br />Clostridium difficile- associated diarrhoea (CDAD) has been reported with use of<br />nearly all antibacterial agents including clarithromycin, and may range in severity<br />from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the<br />normal flora of the colon, which may lead to overgrowth of C. difficile. CDAD<br />must be considered in all patients who present with diarrhoea following antibiotic<br />use. Careful medical history is necessary since CDAD has been reported to occur<br />over two months after the administration of antibacterial agents. Therefore,<br />discontinuation of clarithromycin therapy should be considered regardless of the<br />indication.<br />Microbial testing should be performed and adequate treatment initiated. Drugs<br />inhibiting peristalsis should be avoided.</p><p>There have been post-marketing reports of colchicine toxicity with concomitant<br />use of clarithromycin and colchicine, especially in the elderly, some of which<br />occurred in patients with renal insufficiency. Deaths have been reported in some<br />such patients (see section 4.5). Concomitant administration of clarithromycin and<br />colchicine is contraindicated (see section 4.3).<br />Caution is advised regarding concomitant administration of clarithromycin and<br />triazolobenzodiazepines, such as triazolam, and intravenous or oromucosal<br />midazolam (see section 4.5).</p><p>Cardiovascular Events:<br />Prolongation of the QT interval, reflecting effects on cardiac repolarisation<br />imparting a risk of developing cardiac arrhythmia and torsades de pointes, have<br />been seen in patients treated with macrolides including clarithromycin (see section<br />4.8). Due to increased risk of QT prolongation and ventricular arrhythmias<br />(including torsades de pointes), the use of clarithromycin is contraindicated: in<br />patients taking any of astemizole, cisapride, domperidone, pimozide and<br />terfenadine; in patients who have hypokalaemia; and in patients with a history of<br />QT prolongation or ventricular cardiac arrhythmia (see section 4.3).<br />Furthermore, clarithromycin should be used with caution in the following:<br />&bull; Patients with coronary artery disease, severe cardiac insufficiency,<br />conduction disturbances or clinically relevant bradycardia;<br />&bull; Patients with hypomagnesaemia;<br />&bull; Patients concomitantly taking other medicinal products associated with QT<br />prolongation other than those which are contraindicated<br />Epidemiological studies investigating the risk of adverse cardiovascular outcomes<br />with macrolides have shown variable results. Some observational studies have<br />identified a rare short-term risk of arrhythmia, myocardial infarction and&nbsp;cardiovascular mortality associated with macrolides including clarithromycin.<br />Consideration of these findings should be balanced with treatment benefits when<br />prescribing clarithromycin.<br />Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae to<br />macrolides, it is important that sensitivity testing be performed when prescribing<br />clarithromycin for community-acquired pneumonia. In hospital- acquired<br />pneumonia, clarithromycin should be used in combination with additional<br />appropriate antibiotics.<br />Skin and soft tissue infections of mild to moderate severity: These infections are<br />most often caused by Staphylococcus aureus and Streptococcus pyogenes, both of<br />which may be resistant to macrolides. Therefore, it is important that sensitivity<br />testing be performed. In cases where beta&ndash;lactam antibiotics cannot be used (e.g.<br />allergy), other antibiotics, such as clindamycin, may be the drug of first choice.<br />Currently, macrolides are only considered to play a role in some skin and soft<br />tissue infections, such as those caused by Corynebacterium minutissimum, acne<br />vulgaris, and erysipelas and in situations where penicillin treatment cannot be<br />used.</p><p>In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe<br />cutaneous adverse reactions (SCAR) (e.g. Acute generalised exanthematous<br />pustulosis (AGEP), Stevens-Johnson Syndrome, toxic epidermal necrolysis and<br />drug rash with eosinophilia and systemic symptoms (DRESS)), clarithromycin<br />therapy should be discontinued immediately and appropriate treatment should be<br />urgently initiated.<br />Clarithromycin should be used with caution when administered concurrently with<br />medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).<br />HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin with<br />lovastatin or simvastatin is contraindicated (see section 4.3). Caution should be<br />exercised when prescribing clarithromycin with other statins.<br />Rhabdomyolysis has been reported in patients taking clarithromycin and statins.<br />Patients should be monitored for signs and symptoms of myopathy.<br />In situations where the concomitant use of clarithromycin with statins cannot be<br />avoided, it is recommended to prescribe the lowest registered dose of the statin.<br />Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can<br />be considered (see section 4.5).</p><p>Oral hypoglycaemic agents/Insulin: The concomitant use of clarithromycin and<br />oral hypoglycaemic agents (such as sulphonylurias) and/or insulin can result in<br />significant hypoglycaemia. Careful monitoring of glucose is recommended (see<br />section 4.5).<br />Oral anticoagulants: There is a risk of serious haemorrhage and significant<br />elevations in International Normalized Ratio (INR) and prothrombin time<br />when clarithromycin is co-administered with warfarin (see section 4.5). INR and&nbsp;prothrombin times should be frequently monitored while patients are receiving<br />clarithromycin and oral anticoagulants concurrently.<br />Long-term use may, as with other antibiotics, result in colonisation with increased<br />numbers of non-susceptible bacteria and fungi. If superinfections occur,<br />appropriate therapy should be instituted.<br />Attention should also be paid to the possibility of cross resistance between<br />clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.<br />Excipients<br />This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to<br />say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of the following drugs is strictly contraindicated due to the potential<br />for severe drug interaction effects:<br />Astemizole, cisapride, domperidone, pimozide, and terfenadine: Elevated<br />cisapride levels have been reported in patients receiving clarithromycin and<br />cisapride concomitantly. This may result in QT prolongation and cardiac<br />arrhythmias including ventricular tachycardia, ventricular fibrillation and<br />torsades de pointes. Similar effects have been<br />observed in patients taking clarithromycin and pimozide concomitantly (see<br />section 4.3).<br />Macrolides have been reported to alter the metabolism of terfenadine resulting in<br />increased levels of terfenadine which has occasionally been associated with cardiac<br />arrhythmias, such as QT prolongation, ventricular tachycardia, ventricular<br />fibrillation and torsades de pointes (see section 4.3). In one study in 14 healthy<br />volunteers, the concomitant administration of clarithromycin and terfenadine<br />resulted in 2- to 3-fold increase in the serum level of the acid metabolite of<br />terfenadine and in prolongation of the QT interval which did not lead to any<br />clinically detectable effect. Similar effects have been observed with concomitant<br />administration of astemizole and other macrolides.</p><p>Ergot alkaloids:<br />Post-marketing reports indicate that co-administration of clarithromycin with<br />ergotamine or dihydroergotamine has been associated with acute ergot toxicity<br />characterized by vasospasm, and ischaemia of the extremities and other tissues<br />including the central nervous system. Concomitant administration of<br />clarithromycin and ergot alkaloids is contraindicated (see section 4.3).<br />Oral Midazolam<br />When midazolam was co-administered with clarithromycin tablets (500 mg twice<br />daily), midazolam AUC was increased 7-fold after oral administration of<br />midazolam. Concomitant administration of oral midazolam and clarithromycin is&nbsp;contraindicated (see section 4.3).<br />HMG-CoA Reductase Inhibitors (statins)<br />Concomitant use of clarithromycin with lovastatin or simvastatin is<br />contraindicated (see 4.3) as these statins are extensively metabolized by CYP3A4<br />and concomitant treatment with clarithromycin increases their plasma<br />concentration, which increases the risk of myopathy, including rhabdomyolysis.<br />Reports of rhabdomyolysis have been received for patients taking clarithromycin<br />concomitantly with these statins. If treatment with clarithromycin cannot be<br />avoided, therapy with lovastatin or simvastatin must be suspended during the<br />course of treatment.<br />Caution should be exercised when prescribing clarithromycin with statins. In<br />situations where the concomitant use of clarithromycin with statins cannot be<br />avoided, it is recommended to prescribe the lowest registered dose of the statin.<br />Use of a statin that is not dependent on CYP3A metabolism (e.g.fluvastatin) can be<br />considered. Patients should be monitored for signs and symptoms of myopathy.</p><p>Effects of Other Medicinal Products on Clarithromycin<br />Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine,<br />phenobarbital, St John&rsquo;s wort) may induce the metabolism of clarithromycin. This<br />may result in sub-therapeutic levels of clarithromycin leading to reduced efficacy.<br />Furthermore, it might be necessary to monitor the plasma levels of the CYP3A<br />inducer, which could be increased owing to the inhibition of CYP3A by<br />clarithromycin (see also the relevant product information for the CYP3A4 inducer<br />administered). Concomitant administration of rifabutin and clarithromycin resulted<br />in an increase in rifabutin, and decrease in clarithromycin serum levels together<br />with an increased risk of uveitis.<br />The following drugs are known or suspected to affect circulating concentrations<br />of clarithromycin; clarithromycin dosage adjustment or consideration of<br />alternative treatments may be required.</p><p>Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine<br />Strong inducers of the cytochrome P450 metabolism system such as efavirenz,<br />nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of<br />clarithromycin and thus lower the plasma levels of clarithromycin, while<br />increasing those of 14-OH-clarithromycin, a metabolite that is also<br />microbiologically active. Since the microbiological activities of clarithromycin<br />and 14-OH-clarithromycin are different for different bacteria, the intended<br />therapeutic effect could be impaired during concomitant administration of<br />clarithromycin and enzyme inducers.<br />Etravirine<br />Clarithromycin exposure was decreased by etravirine; however, concentrations of<br />the active metabolite, 14-OH-clarithromycin, were increased. Because 14- OHclarithromycin<br />has reduced activity against Mycobacterium avium complex<br />(MAC), overall activity against this pathogen may be altered; therefore alternatives<br />to clarithromycin should be considered for the treatment of MAC.</p><p>Fluconazole<br />Concomitant administration of fluconazole 200 mg daily and clarithromycin 500<br />mg twice daily to 21 healthy volunteers led to increases in the mean steady-state<br />minimum clarithromycin concentration (Cmin) and area under the curve (AUC) of<br />33% and 18% respectively. Steady state concentrations of the active metabolite 14-<br />OH-clarithromycin were not significantly affected by concomitant administration<br />of fluconazole. No clarithromycin dose adjustment is necessary.</p><p>Ritonavir<br />A pharmacokinetic study demonstrated that the concomitant administration of<br />ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours<br />resulted in a marked inhibition of the metabolism of clarithromycin. The<br />clarithromycin Cmax increased by 31%, Cmin increased 182% and AUC increased<br />by 77% with concomitant administration of ritonavir. An essentially complete<br />inhibition of the formation of 14-OH-clarithromycin was noted.<br />Because of the large therapeutic window for clarithromycin, no dosage reduction<br />should be necessary in patients with normal renal function. However, for patients<br />with renal impairment, the following dosage adjustments should be considered: For<br />patients with CLCR 30 to 60 mL/min the dose of clarithromycin should be reduced<br />by 50%. For patients with CLCR &lt;30 mL/min the dose of clarithromycin should be<br />decreased by 75%. Doses of clarithromycin greater than 1 g /day should not be coadministered<br />with ritonavir.<br />Similar dose adjustments should be considered in patients with reduced renal<br />function when ritonavir is used as a pharmacokinetic enhancer with other HIV<br />protease inhibitors including atazanavir and saquinavir (see section below, Bidirectional<br />drug interactions).</p><p>Effect of Clarithromycin on Other Medicinal Products<br />CYP3A-based interactions<br />Co-administration of clarithromycin, which is known to inhibit CYP3A, and a<br />drug primarily metabolised by CYP3A may be associated with elevations in drug<br />concentrations that could increase or prolong both therapeutic and adverse effects<br />of the concomitant drug.<br />The use of clarithromycin is contraindicated in patients receiving the CYP3A<br />substrates astemizole, cisapride, domperidone, pimozide and terfenadine due to the<br />risk of QT prolongation and cardiac arrhythmias, including ventricular<br />tachycardia, ventricular fibrillation, and torsades de pointes (see sections 4.3 and<br />4.4).</p><p>The use of clarithromycin is also contraindicated with ergot alkaloids, oral<br />midazolam, HMG CoA reductase inhibitors metabolised mainly by CYP3A4 (e.g.<br />lovastatin and simvastatin), colchicine, ticagrelor and ranolazine (see section 4.3).<br />Caution is required if clarithromycin is co-administered with other drugs known to<br />be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow<br />safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolised<br />by this enzyme. Dosage adjustments may be considered, and when possible, serum<br />concentrations of drugs primarily metabolised by CYP3A should be monitored</p><p>closely in patients concurrently receiving clarithromycin. Drugs or drug classes that<br />are known or suspected to be metabolised by the same CYP3A isozyme include<br />(but this list is not comprehensive) alprazolam, carbamazepine, cilostazole,<br />ciclosporin, disopyramide, ibrutinib, methylprednisolone, midazolam (intravenous),<br />omeprazole, oral anticoagulants (e.g. warfarin), atypical antipsychotics (e.g.<br />quetiapine), quinidine, rifabutin, sildenafil, sirolimus, tacrolimus, triazolam and<br />vinblastine.<br />Drugs interacting by similar mechanisms through other isozymes within the<br />cytochrome P450 system include phenytoin, theophylline and valproate.<br />Antiarrhythmics<br />There have been post-marketed reports of torsades de pointes occurring with the<br />concurrent use of clarithromycin and quinidine or disopyramide.<br />Electrocardiograms should be monitored for QT prolongation during coadministration<br />of clarithromycin with these drugs. Serum levels of quinidine and<br />disopyramide should be monitored during clarithromycin therapy.</p><p>There have been post marketing reports of hypoglycemia with the concomitant<br />administration of clarithromycin and disopyramide. Therefore blood glucose levels<br />should be monitored during concomitant administration of clarithromycin and<br />disopyramide.<br />Oral hypoglycemic agents/Insulin<br />With certain hypoglycemic drugs such as nateglinide, and repaglinide, inhibition of<br />CYP3A enzyme by clarithromycin may be involved and could cause hypolgycemia<br />when used concomitantly. Careful monitoring of glucose is recommended.<br />Omeprazole<br />Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole<br />(40 mg daily) to healthy adult subjects. The steady-state plasma concentrations of<br />omeprazole were increased (Cmax, AUC0-24, and t1/2 increased by 30%, 89%,<br />and 34%, respectively), by the concomitant administration of clarithromycin. The<br />mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone<br />and 5.7 when omeprazole was co-administered with clarithromycin.</p><p>Sildenafil, tadalafil and vardenafil<br />Each of these phosphodiesterase inhibitors is metabolised, at least in part, by<br />CYP3A, and CYP3A may be inhibited by concomitantly administered<br />clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil or<br />vardenafil would likely result in increased phosphodiesterase inhibitor exposure.<br />Reduction of sildenafil, tadalafil and vardenafil dosages should be considered when<br />these drugs are co-administered with clarithromycin.<br />Theophylline, carbamazepine<br />Results of clinical studies indicate that there was a modest but statistically<br />significant (p&le; 0.05) increase of circulating theophylline or carbamazepine levels<br />when either of these drugs were administered concomitantly with clarithromycin.<br />Dose reduction may need to be considered.</p><p>Tolterodine<br />The primary route of metabolism for tolterodine is via the 2D6 isoform of<br />cytochrome P450 (CYP2D6). However, in a subset of the population devoid of<br />CYP2D6, the identified pathway of metabolism is via CYP3A. In this population<br />subset, inhibition of CYP3A results in significantly higher serum concentrations of<br />tolterodine. A reduction in tolterodine dosage may be necessary in the presence of<br />CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metaboliser<br />population.<br />Triazolobenzodiazepines (e.g., alprazolam, midazolam, triazolam)<br />When midazolam was co-administered with clarithromycin tablets (500 mg twice<br />daily), midazolam AUC was increased 2.7-fold after intravenous administration of<br />midazolam. If intravenous midazolam is co-administered with clarithromycin, the<br />patient must be closely monitored to allow dose adjustment. Drug delivery of<br />midazolam via oromucosal route, which could bypass pre-systemic elimination of<br />the drug, will likely result in a similar interaction to that observed after intravenous<br />midazolam rather than oral administration. The same precautions should also apply<br />to other benzodiazepines that are metabolised by CYP3A, including triazolam and<br />alprazolam. For benzodiazepines which are not dependent on CYP3A for their<br />elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction<br />with clarithromycin is unlikely.</p><p>There have been post-marketing reports of drug interactions and central nervous<br />system (CNS) effects (e.g., somnolence and confusion) with the concomitant use<br />of clarithromycin and triazolam. Monitoring the patient for increased CNS<br />pharmacological effects is suggested.</p><p>Other drug interactions<br />Colchicine<br />Colchicine is a substrate for both CYP3A and the efflux transporter, P- glycoprotein<br />(Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp.<br />When clarithromycin and colchicine are administered together, inhibition of Pgp<br />and/or CYP3A by clarithromycin may lead to increased exposure to colchicine (see<br />section 4.3 and 4.4).<br />Digoxin<br />Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp).<br />Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are<br />administered together, inhibition of Pgp by clarithromycin may lead to increased<br />exposure to digoxin. Elevated digoxin serum concentrations in patients receiving<br />clarithromycin and digoxin concomitantly have also been reported in post<br />marketing surveillance. Some patients have shown clinical signs consistent with<br />digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin<br />concentrations should be carefully monitored while patients are receiving digoxin<br />and clarithromycin simultaneously.</p><p>Zidovudine<br />Simultaneous oral administration of clarithromycin tablets and zidovudine to HIVinfected<br />adult patients may result in decreased steady-state zidovudine</p><p>concentrations. Because clarithromycin appears to interfere with the absorption of<br />simultaneously administered oral zidovudine, this interaction can be largely avoided<br />by staggering the doses of clarithromycin and zidovudine to allow for a 4-hour<br />interval between each medication. This interaction does not appear to occur in<br />paediatric HIV-infected patients taking clarithromycin suspension with zidovudine<br />or dideoxyinosine. This interaction is unlikely when clarithromycin is administered<br />via intravenous infusion.<br />Phenytoin and Valproate<br />There have been spontaneous or published reports of interactions of CYP3A<br />inhibitors, including clarithromycin with drugs not thought to be metabolised by<br />CYP3A (e.g. phenytoin and valproate). Serum level determinations are<br />recommended for these drugs when administered concomitantly with<br />clarithromycin. Increased serum levels have been reported.</p><p>Bi-directional drug interactions<br />Atazanavir<br />Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and<br />there is evidence of a bi-directional drug interaction. Co-administration of<br />clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily) resulted<br />in a 2-fold increase in exposure to clarithromycin and a 70% decrease in exposure<br />to 14-OH-clarithromycin, with a 28% increase in the AUC of atazanavir. Because<br />of the large therapeutic window for clarithromycin, no dosage reduction should be<br />necessary in patients with normal renal function. For patients with moderate renal<br />function (creatinine clearance 30 to<br />60 mL/min), the dose of clarithromycin should be decreased by 50%. For patients<br />with creatinine clearance &lt;30 mL/min, the dose of clarithromycin should be<br />decreased by 75% using an appropriate clarithromycin formulation. Doses of<br />clarithromycin greater than 1000 mg per day should not be co- administered with<br />protease inhibitors.</p><p>Calcium Channel Blockers<br />Caution is advised regarding the concomitant administration of clarithromycin and<br />calcium channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine,<br />diltiazem) due to the risk of hypotension. Plasma concentrations<br />of clarithromycin as well as calcium channel blockers may increase due to the<br />interaction. Hypotension, bradyarrhythmias and lactic acidosis have been observed<br />in patients taking clarithromycin and verapamil concomitantly.<br />Itraconazole<br />Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A,<br />leading to a bidirectional drug interaction. Clarithromycin may increase the plasma<br />levels of itraconazole, while itraconazole may increase the plasma levels of<br />clarithromycin. Patients taking itraconazole and clarithromycin concomitantly<br />should be monitored closely for signs or symptoms of increased or prolonged<br />pharmacologic effect.</p><p>Saquinavir<br />Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and&nbsp;there is evidence of a bi-directional drug interaction. Concomitant administration<br />of clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules, 1200<br />mg three times daily) to 12 healthy volunteers resulted in steady-state AUC and<br />Cmax values of saquinavir which were 177% and 187% higher than those seen<br />with saquinavir alone. Clarithromycin AUC and Cmax values were approximately<br />40% higher than those seen with clarithromycin alone. No dose adjustment is<br />required when the two drugs are co-administered for a limited time at the<br />doses/formulations studied.<br />Observations from drug interaction studies using the soft gelatin capsule<br />formulation may not be representative of the effects seen using the saquinavir hard<br />gelatin capsule. Observations from drug interaction studies performed with<br />saquinavir alone may not be representative of the effects seen with<br />saquinavir/ritonavir therapy. When saquinavir is co-administered with ritonavir,<br />consideration should be given to the potential effects of ritonavir on clarithromycin<br />(see section 4.5: Ritonavir).<br />Patients taking oral contraceptives should be warned that if diarrhoea, vomiting or<br />breakthrough bleeding occur there is a possibility of contraceptive failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of clarithromycin for use during pregnancy has not been established.<br />Based on variable results obtained from studies in mice, rats, rabbits and<br />monkeys, the possibility of adverse effects on embryofoetal development<br />cannot be excluded. Therefore, use during pregnancy is not advised without<br />carefully weighing the benefits against risk.</p><p>Breast-feeding<br />The safety of clarithromycin for using during breast-feeding of infants has not been<br />established. Clarithromycin is excreted into human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive<br />or use machines. The potential for<br />dizziness, vertigo, confusion and disorientation, which may occur with<br />the medication, should be taken into account before patients<br />drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile<br />The most frequent and common adverse reactions related to clarithromycin<br />therapy for both adult and paediatric populations are abdominal pain, diarrhoea,<br />nausea, vomiting and taste perversion. These adverse reactions are usually mild<br />in intensity and are consistent with the known safety profile of macrolide<br />antibiotics (see section b of section 4.8).&nbsp;There was no significant difference in the incidence of these gastrointestinal<br />adverse reactions during clinical trials between the patient population with or<br />without pre- existing mycobacterial infections.</p><p>b. Tabulated summary of adverse reactions<br />The following table displays adverse reactions reported in clinical trials and from<br />post-marketing experience with clarithromycin immediate-release tablets,<br />granules for oral suspension, powder for solution for injection, extended-release<br />tablets and modified-release tablets.<br />The reactions considered at least possibly related to clarithromycin are<br />displayed by system organ class and frequency using the following<br />convention: very common (&ge;1/10), common (&ge; 1/100 to &lt; 1/10), uncommon<br />(&ge;1/1,000 to &lt; 1/100) and not known (adverse reactions from post-marketing<br />experience; cannot be estimated from the available data). Within each<br />frequency grouping, adverse reactions are presented in order of decreasing<br />seriousness when the seriousness could be assessed.</p><table border="1" cellspacing="1" cellpadding="1" style="width:819px"><tbody><tr><td style="width:117px">System<br />Organ Class</td><td style="width:197px">Very<br />common<br />&ge;1/10</td><td style="width:184px">Common<br />&ge; 1/100 to &lt;<br />1/10</td><td style="width:146px">Uncommon<br />&ge;1/1,000 to &lt; 1/100</td><td style="width:211px">Not Known*<br />(cannot be estimated<br />from the available<br />data)</td></tr><tr><td style="width:117px">Infections<br />and<br />infestations</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Cellulitis1,<br />candidiasis,<br />gastroenteritis2,<br />infection3, vaginal<br />infection</td><td style="width:211px">Pseudomembranous<br />colitis, erysipelas,</td></tr><tr><td style="width:117px">Blood and<br />lymphatic<br />system</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Leukopenia,<br />neutropenia4,<br />thrombocythaemia3,<br />eosinophilia4</td><td style="width:211px">Agranulocytosis,<br />thrombocytopenia</td></tr><tr><td style="width:117px">Immune<br />system<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Anaphylactoid<br />reaction1,<br />hypersensitivity</td><td style="width:211px">Anaphylactic reaction.<br />angioedema</td></tr><tr><td style="width:117px">Metabolism<br />and nutrition<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Anorexia, decreased<br />appetite</td><td style="width:211px">&nbsp;</td></tr><tr><td style="width:117px">Psychiatric<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">Insomnia</td><td style="width:146px">Anxiety,<br />nervousness3,</td><td style="width:211px">Psychotic disorder,<br />confusional state5,<br />depersonalisation,<br />depression,<br />disorientation,<br />hallucination,<br />abnormal dreams,<br />mania</td></tr><tr><td style="width:117px">Nervous<br />system<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">Dysgeusia,<br />headache</td><td style="width:146px">Loss of<br />consciousness1,<br />dyskinesia1,<br />dizziness,<br />somnolence5, tremor</td><td style="width:211px">Convulsion, ageusia,<br />parosmia, anosmia,<br />paraesthesia</td></tr><tr><td style="width:117px">Ear and<br />labyrinth<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Vertigo, hearing<br />impaired, tinnitus</td><td style="width:211px">Deafness</td></tr><tr><td style="width:117px">Cardiac<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Cardiac arrest1,<br />atrial fibrillation1,<br />electrocardiogram<br />QT prolonged,<br />extrasystoles1,<br />palpitations</td><td style="width:211px">Torsades de pointes,<br />ventricular<br />tachycardia,<br />ventricular fibrillation</td></tr><tr><td style="width:117px">Vascular<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">Vasodilation1</td><td style="width:146px">&nbsp;</td><td style="width:211px">Haemorrhage</td></tr><tr><td style="width:117px">Respiratory,<br />thoracic and<br />mediastinal<br />disorder</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Asthma1, epistaxis2,<br />pulmonary<br />embolism1</td><td style="width:211px">&nbsp;</td></tr><tr><td style="width:117px">Gastrointesti<br />nal disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">Diarrhoea,<br />vomiting,<br />dyspepsia,<br />nausea,<br />abdominal<br />pain</td><td style="width:146px">Oesophagitis1,<br />gastrooesophageal<br />reflux disease2,<br />gastritis, proctalgia2,<br />stomatitis, glossitis,<br />abdominal<br />distension4,<br />constipation, dry<br />mouth, eructation,<br />flatulence,</td><td style="width:211px">Pancreatitis acute,<br />tongue discolouration,<br />tooth discolouration</td></tr><tr><td style="width:117px">Hepatobiliar<br />y disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">Liver<br />function test<br />abnormal</td><td style="width:146px">Cholestasis4,<br />hepatitis4, alanine<br />aminotransferase<br />increased, aspartate<br />aminotransferase<br />increased, gammaglutamyltransferase<br />increased4</td><td style="width:211px">Hepatic failure,<br />jaundice<br />hepatocellular</td></tr><tr><td style="width:117px">Skin and<br />subcutaneous<br />tissue<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">Rash,<br />hyperhidrosis</td><td style="width:146px">Dermatitis bullous1,<br />pruritus, urticaria,<br />rash maculopapular3</td><td style="width:211px">Severe cutaneous<br />adverse reactions<br />(SCAR) (e.g. Acute<br />generalised<br />exanthematous<br />pustulosis<br />(AGEP),Stevens-<br />Johnson syndrome,<br />toxic epidermal<br />necrolysis, drug rash<br />with eosinophilia and<br />systemic symptoms<br />(DRESS)), acne</td></tr><tr><td style="width:117px">Musculoskel<br />etal and<br />connective<br />tissue&nbsp;disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Muscle spasms3,<br />musculoskeletal<br />stiffness1, myalgia2</td><td style="width:211px">Rhabdomyolysis2,6,<br />myopathy</td></tr><tr><td style="width:117px">Renal and<br />urinary<br />disorders</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Blood creatinine<br />increased1, blood<br />urea increased1</td><td style="width:211px">Renal failure,<br />nephritis interstitial</td></tr><tr><td style="width:117px">General<br />disorders and<br />administratio<br />n site<br />conditions</td><td style="width:197px">Injection site<br />phlebitis1</td><td style="width:184px">Injection site<br />pain1,<br />injection site<br />inflammation<br />1</td><td style="width:146px">Malaise4, pyrexia3,<br />asthenia, chest pain4,<br />chills4, fatigue4</td><td style="width:211px">&nbsp;</td></tr><tr><td style="width:117px">Investigations</td><td style="width:197px">&nbsp;</td><td style="width:184px">&nbsp;</td><td style="width:146px">Albumin globulin<br />ratio abnormal1,<br />blood alkaline<br />phosphatase<br />increased4,<br />blood lactate<br />dehydrogenase<br />increased4</td><td style="width:211px">International<br />normalised ratio<br />increased,<br />prothrombin time<br />prolonged, urine<br />colour abnormal</td></tr></tbody></table><p>1 ADRs reported only for the Powder for Concentrate for Solution&nbsp;</p><p>2 for Infusion formulation</p><p>3A DRs reported only for the Extended-Release Tablets formulation</p><p>4 ADRs reported only for the Granules for Oral Suspension formulation ADRs reported only for the Immediate-Release Tablets formulation<br />5, 6, See section c)</p><p>* Because these reactions are reported voluntarily from a population of<br />uncertain size, it is not always possible to reliably estimate their frequency or<br />establish a causal relationship to drug exposure. Patient exposure is estimated<br />to be greater than 1 billion patient treatment days for clarithromycin.</p><p>&nbsp;</p><p>c. Description of selected adverse reactions<br />Injection site phlebitis, injection site pain, and injection site inflammation are specific to<br />the clarithromycin intravenous formulation.<br />In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly<br />with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).<br />There have been post-marketing reports of drug interactions and central nervous system<br />(CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin<br />and triazolam. Monitoring the patient for increased CNS pharmacological effects is<br />suggested (see section 4.5).<br />There have been rare reports of clarithromycin ER tablets in the stool, many of which<br />have occurred in patients with anatomic (including ileostomy or colostomy) or functional<br />gastrointestinal disorders with shortened GI transit times. In several reports, tablet<br />residues have occurred in the context of diarrhoea. It is recommended that patients who<br />experience tablet residue in the stool and no improvement in their condition should be<br />switched to a different clarithromycin formulation (e.g. suspension) or another antibiotic.<br />Special population: Adverse Reactions in Immunocompromised Patients (see section e).</p><p>&nbsp;</p><p>d. Paediatric populations<br />Clinical trials have been conducted using clarithromycin paediatric suspension in<br />children 6 months to 12 years of age. Therefore, children under 12 years of age should<br />use clarithromycin paediatric suspension.<br />Frequency, type and severity of adverse reactions in children are expected to be the same<br />as in adults.</p><p>&nbsp;</p><p>e. Other special populations<br />Immunocompromised patients<br />In AIDS and other immunocompromised patients treated with the higher doses of<br />clarithromycin over long periods of time for mycobacterial infections, it was often<br />difficult to distinguish adverse events possibly associated with clarithromycin<br />administration from underlying signs of Human Immunodeficiency Virus (HIV) disease or<br />intercurrent illness.<br />In adult patients, the most frequently reported adverse reactions by patients treated with<br />total daily doses of 1000 mg and 2000mg of clarithromycin were: nausea, vomiting, taste<br />perversion, abdominal pain, diarrhoea, rash, flatulence, headache, constipation, hearing<br />disturbance, Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic<br />Pyruvate Transaminase (SGPT) elevations. Additional low-frequency events included<br />dyspnoea, insomnia and dry mouth. The incidences were comparable for patients treated<br />with 1000mg and 2000mg, but were generally<br />about 3 to 4 times as frequent for those patients who received total daily doses of 4000mg<br />of clarithromycin.</p><p>In these immunocompromised patients, evaluations of laboratory values were made by<br />analysing those values outside the seriously abnormal level (i.e. the extreme high or low<br />limit) for the specified test. On the basis of these criteria, about 2% to 3% of those<br />patients who received 1000mg or 2000mg of clarithromycin daily had seriously abnormal<br />elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet<br />counts. A lower percentage of patients in these two dosage groups also had elevated<br />Blood Urea Nitrogen levels. Slightly higher incidences of abnormal values were noted<br />for patients who received 4000mg daily for all parameters except White Blood Cell.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is<br />important. It allows continued monitoring of the benefit/risk balance of the medicinal<br />product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>To report any side effect(s):<br />-National Pharmacovigilance Center (NPC)<br />o Fax: +966-1-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />oToll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be<br />expected to produce gastro-intestinal symptoms. One patient who had a history of<br />bipolar disorder ingested 8 grams of clarithromycin and showed altered mental<br />status, paranoid behaviour, hypokalaemia and hypoxaemia.<br />Adverse reactions accompanying overdosage should be treated by the prompt<br />elimination of unabsorbed drug and supportive measures. As with other<br />macrolides, clarithromycin serum levels are not expected to be appreciably<br />affected by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />ATC Classification:<br />Pharmacotherapeutic group: Antibacterial for systemic use, macrolide<br />ATC-Code: J01FA09<br />Mode of Action:<br />Clarithromycin is an antibiotic belonging to the macrolide antibiotic group. It<br />exerts its antibacterial action by selectively binding to the 50s ribosomal sub- unit<br />of susceptible bacteria preventing translocation of activitate amino acids. It<br />inhibits the intracellular protein synthesis of susceptible bacteria.<br />The 14-hydroxy metabolite of clarithromycin, a product of parent drug metabolism<br />also has antimicrobial activity. The metabolite is less active than<br />the parent compound for most organisms, including mycobacterium spp. An<br />exception is Haemophilus influenza where the 14-hydroxy metabolite is two- fold<br />more active than the parent compound.<br />Clarithromycin is usually active against the following organisms in vitro:<br />Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible);<br />Streptococcus pyogenes (Group A beta-hemolytic streptococci) alphahemolytic<br />streptococci (viridans group); Streptococcus (Diplococcus)<br />pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.</p><p>Gram-negative Bacteria: Haemophilus influenzae, Haemophilus parainfluenzae,<br />Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae; Legionella<br />pneumophila, Bordetella pertussis, Helicobacter pylori; Campylobacter jejuni.<br />Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.<br />Other Organisms: Chlamydia trachomatis; Mycobacterium avium, Mycobacterium<br />leprae; Mycobacterum kansasii; Mycobacterium chelonae; Mycobacterium<br />fortuitum; Mycobacterium intracellulare.<br />Anaerobes: Macrolide-susceptible Bacteroides fragilis, Clostridium perfringens;<br />Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.<br />Clarithromycin has bactericidal activity against several bacterial strains. The<br />organisms include Haemophilus influenzae, Streptococcus pneumoniae,<br />Streptococcus pyogenes, Streptococcus agalactiae, Moraxella (Branhamella)<br />catarrhalis, Neisseria gonorrhoeae, H. pylori and Campylobacter spp.</p><p>Breakpoints<br />The following breakpoints have been established by the European Committee for<br />Antimicrobial Susceptibility Testing (EUCAST).</p><table border="1" cellspacing="1" cellpadding="1" style="width:676px"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td style="width:177px">&nbsp;</td></tr><tr><td>Microorganism</td><td>Susceptible (&le;)</td><td style="width:177px">Resistant (&gt;)</td></tr><tr><td>Staphylococcus spp</td><td>1 mg/L</td><td style="width:177px">2 mg/L</td></tr><tr><td>Streptococcus A, B, C<br />and G</td><td>0.25 mg/L</td><td style="width:177px">0.5 mg/L</td></tr><tr><td>Streptococcus<br />pneumonia</td><td>0.25 mg/L</td><td style="width:177px">0.5 mg/L</td></tr><tr><td>Viridans group<br />streptococcus</td><td>IE</td><td style="width:177px">IE</td></tr><tr><td>Haemophilus spp.</td><td>1 mg/L</td><td style="width:177px">32 mg/L</td></tr><tr><td>Moraxella<br />catarrhalis</td><td>0.25 mg/L</td><td style="width:177px">0.5 mg/L 1</td></tr><tr><td>Helicobacter pylori</td><td>0.25 mg/L1</td><td style="width:177px">0.5 mg/L</td></tr></tbody></table><p>1 The breakpoints are based on epidemiological cut-off values (ECOFFs),<br />which distinguish wild-type isolates from those with reduces susceptibility.<br />&ldquo;IE&quot; indicates that there is insufficient evidence that the species in<br />question is a good target for therapy with the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>H. pylori is associated with acid peptic disease including duodenal ulcer and<br />gastric ulcer in which about 95% and 80% of patients respectively are infected<br />with the agent. H. pylori is also implicated as a major contribution factor in the&nbsp;development of gastritis and ulcer recurrence in such patients.<br />Clarithromycin has been used in small numbers of patients in other treatment<br />regimens. Possible kinetic interactions have not been fully investigated. These<br />regimens include:<br />Clarithromycin plus tinidazole and omeprazole; clarithromycin plus tetracycline,<br />bismuth subsalicylate and ranitidine; clarithromycin plus ranitidine alone.<br />Clinical studies using various different H. pylori eradication regimens have shown<br />that eradication of H. pylori prevents ulcer recurrence.</p><p>Clarithromycin is rapidly and well absorbed from the gastro-intestinal tract after<br />oral administration of Clarithromycin tablets. The microbiologically active<br />metabolite 14- hydroxyclarithromycin is formed by first pass metabolism.<br />Clarithromycin may be given without regard to meals as food does not affect the<br />extent of bioavailability of Clarithromycin tablets. Food does slightly delay the<br />onset of absorption of clarithromycin and formation of the 14-hydroxymetabolite.<br />The pharmacokinetics of clarithromycin are non linear; however, steady-state is<br />attained within 2 days of dosing. At 250 mg b.i.d. 15-20% of unchanged drug is<br />excreted in the urine. With 500 mg b.i.d. daily dosing urinary excretion is greater<br />(approximately 36%). The 14- hydroxyclarithromycin is the major urinary<br />metabolite and accounts for 10-15% of the dose. Most of the remainder of the dose<br />is eliminated in the faeces, primarily via the bile. 5-10% of the parent drug is<br />recovered from the faeces.</p><p>When clarithromycin 500 mg is given three times daily, the clarithromycin plasma<br />concentrations are increased with respect to the 500 mg twice daily dosage.<br />Clarithromycin provides tissue concentrations that are several times higher than the<br />circulating drug levels. Increased levels have been found in both tonsillar and lung<br />tissue. Clarithromycin is 80% bound to plasma proteins at therapeutic levels.<br />Clarithromycin also penetrates the gastric mucus. Levels of clarithromycin in<br />gastric mucus and gastric tissue are higher when clarithromycin is co-administered<br />with omeprazole than when clarithromycin is administered alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In acute mouse and rat studies, the median lethal dose was greater than the highest<br />feasible dose for administration (5g/kg).</p><p>In repeated dose studies, toxicity was related to dose, duration of treatment and<br />species. Dogs were more sensitive than primates or rats. The major clinical signs at<br />toxic doses included emesis, weakness, reduced food consumption and weight<br />gain, salivation, dehydration and hyperactivity. In all species the liver was the<br />primary target organ at toxic doses. Hepatotoxicity was detectable by early<br />elevations of liver function tests. Discontinuation of the drug generally resulted in<br />a return to or toward normal results. Other tissues less commonly affected<br />included the stomach, thymus and other lymphoid tissues and the kidneys. At near<br />therapeutic doses, conjunctival injection and lacrimation occurred only in dogs. At<br />a massive dose of 400mg/kg/day, some dogs and monkeys developed corneal<br />opacities and/or oedema.</p><p>Fertility and reproduction studies in rats have shown no adverse effects.<br />Teratogenicity studies in rats (Wistar (p.o.) and Sprague-Dawley (p.o. and i.v.)),<br />New Zealand White rabbits and cynomolgous monkeys failed to demonstrate any<br />teratogenicity from clarithromycin. However, a further similar study in Sprague-<br />Dawley rats indicated a low (6%) incidence of cardiovascular abnormalities which<br />appeared to be due to spontaneous expression of genetic changes. Two mouse<br />studies revealed a variable incidence (3-30%) of cleft palate and embryonic loss<br />was seen in monkeys but only at dose levels which were clearly toxic to the<br />mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet Core Croscarmellose<br />sodium Cellulose,<br />microcrystalline Silicon<br />dioxide<br />Povidone Stearic<br />acid<br />Magnesium stearate Talc<br />Tablet Coating, Colour and Gloss Coating Hypromellose<br />Sorbitan oleate Propylene<br />glycol Titanium dioxide<br />Vanillin<br />Quinoline Yellow (E104 aluminium lake)<br />Hydroxypropylcellulose<br />Sorbic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg; C<br />Store in a dry place, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets in a PVC/ PVdC aluminium foil blister pack. Pack sizes are 14, 20, 28, 42,<br />84,168 tablets in a carton with a patient leaflet.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratories Ltd.
Abbott House, Vanwall Business park
Vanwall Road, Maidenhead Berkshire
SL6 4XE, UK
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2019 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>